140 related articles for article (PubMed ID: 21157932)
1. Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran.
Rahmadi M; Narita M; Yamashita A; Imai S; Kuzumaki N; Suzuki T
Synapse; 2011 Jul; 65(7):652-7. PubMed ID: 21157932
[TBL] [Abstract][Full Text] [Related]
2. The effect of clomipramine on wake/sleep and orexinergic expression in rats.
Feng P; Hu Y; Li D; Vurbic D; Fan H; Wang S; Strohl KP
J Psychopharmacol; 2009 Jul; 23(5):559-66. PubMed ID: 18562438
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
Gervasoni D; Panconi E; Henninot V; Boissard R; Barbagli B; Fort P; Luppi PH
Pharmacol Biochem Behav; 2002 Oct; 73(3):557-63. PubMed ID: 12151030
[TBL] [Abstract][Full Text] [Related]
4. A possible mechanism underlying an antidepressive-like effect of Kososan, a Kampo medicine, via the hypothalamic orexinergic system in the stress-induced depression-like model mice.
Ito N; Yabe T; Nagai T; Oikawa T; Yamada H; Hanawa T
Biol Pharm Bull; 2009 Oct; 32(10):1716-22. PubMed ID: 19801833
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
Kurose K; Hiratsuka K; Ishiwata K; Nishikawa J; Nonen S; Azuma J; Kato M; Wakeno M; Okugawa G; Kinoshita T; Kurosawa T; Hasegawa R; Saito Y
Psychiatry Res; 2012 Aug; 198(3):424-9. PubMed ID: 22445761
[TBL] [Abstract][Full Text] [Related]
6. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
[TBL] [Abstract][Full Text] [Related]
7. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
Morishita S; Arita S
Eur Psychiatry; 2004 Aug; 19(5):315-6. PubMed ID: 15276667
[No Abstract] [Full Text] [Related]
9. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
[TBL] [Abstract][Full Text] [Related]
10. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.
Eriksson KS; Sergeeva O; Brown RE; Haas HL
J Neurosci; 2001 Dec; 21(23):9273-9. PubMed ID: 11717361
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of milnacipran and paroxetine in outpatients with major depression.
Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
[TBL] [Abstract][Full Text] [Related]
12. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB
Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
14. Brain orexins and wake regulation in rats exposed to maternal deprivation.
Feng P; Vurbic D; Wu Z; Strohl KP
Brain Res; 2007 Jun; 1154():163-72. PubMed ID: 17466285
[TBL] [Abstract][Full Text] [Related]
15. Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington's Disease Mice.
Kantor S; Varga J; Kulkarni S; Morton AJ
Neurotherapeutics; 2017 Oct; 14(4):1120-1133. PubMed ID: 28653279
[TBL] [Abstract][Full Text] [Related]
16. Mice deficient in the interferon type I receptor have reduced REM sleep and altered hypothalamic hypocretin, prolactin and 2',5'-oligoadenylate synthetase expression.
Bohnet SG; Traynor TR; Majde JA; Kacsoh B; Krueger JM
Brain Res; 2004 Nov; 1027(1-2):117-25. PubMed ID: 15494163
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological and neurochemical characterization of the effect of repeated treatment with milnacipran on the rat serotonergic and noradrenergic systems.
Tachibana K; Matsumoto M; Koseki H; Togashi H; Kojima T; Morimoto Y; Yoshioka M
J Psychopharmacol; 2006 Jul; 20(4):562-9. PubMed ID: 16401668
[TBL] [Abstract][Full Text] [Related]
18. Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice.
Willie JT; Takahira H; Shibahara M; Hara J; Nomiyama M; Yanagisawa M; Sakurai T
J Mol Neurosci; 2011 Feb; 43(2):155-61. PubMed ID: 20711757
[TBL] [Abstract][Full Text] [Related]
19. Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice.
Deng BS; Nakamura A; Zhang W; Yanagisawa M; Fukuda Y; Kuwaki T
J Appl Physiol (1985); 2007 Nov; 103(5):1772-9. PubMed ID: 17717124
[TBL] [Abstract][Full Text] [Related]
20. Action of modafinil through histaminergic and orexinergic neurons.
Ishizuka T; Murotani T; Yamatodani A
Vitam Horm; 2012; 89():259-78. PubMed ID: 22640618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
